The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,238.00
Bid: 12,236.00
Ask: 12,238.00
Change: -8.00 (-0.07%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

More to come as bear capitulation drives recent risk rally

Mon, 19th Jun 2023 10:48

STOXX 600 down 0.5%

*

Major indices in the red

*

U.S. markets closed for Juneteenth holiday

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

MORE TO COME AS BEAR CAPITULATION DRIVES RECENT RISK RALLY (0948 GMT)

Stock markets are taking a breather on Monday after a rally which has seen the DAX close at a record high on Friday, the Nasdaq surge almost 38% year-to-date and the S&P 500 enter a technical bull market.

Ben Laidler, global markets strategist at eToro, says positive fundamentals have driven the rally but poor investor sentiment has also been important.

"We are now in a positive ‘pain trade’, as previously bearish investors capitulate and chase stocks higher," Laidler writes.

"Poor sentiment has had two benefits, protecting on the downside and is now magnifying the upside."

Laidler says this "bear capitulation" can be powerful and last for a while before sentiment becomes too bullish and the dynamic reverses.

Meanwhile, Jefferies chief financial economist Europe Mohit Kumar says they are retaining their small long position in risky assets amid the recent buoyant mood.

"There is little in terms of data between now and the U.S. payrolls which would dent the recent optimism," Kumar says.

"We still struggle to see significant upside from current levels, but believe that the path of least resistance is for modestly higher risky assets."

(Samuel Indyk)

CAUTIOUS START FOR EUROPE (0811 GMT)

European equity markets are taking a breather on Monday after a strong performance last week that saw Germany's DAX close at a record high and broader European shares notch their biggest weekly gain in two months.

The pan-European benchmark STOXX 600 index is down around 0.6%, while the DAX , CAC 40 and FTSE 100 are down 0.3%-0.6%.

"Investors are lacking Monday motivation today, as caution returns amid worries about global growth," says Susannah Streeter, head of money and markets, Hargreaves Lansdown.

"European indices have opened lower ... as investors mull what's ahead for the path of interest rates, given the stubbornness of inflation, while concerns persist about China's recovery losing steam."

Shares in Franco-German lab supplies maker Sartorius are down around 13% after the company cut its margin and sales forecast.

Aerospace and Defence stocks are a rare bright spot, as attention falls on Paris, where the world's largest aviation trade show is kicking off, with airlines going into the event with growing demand expectations.

Here's your opening snapshot:

(Samuel Indyk)

MONDAY BLUES FOR EUROPEAN FUTURES (0635 GMT)

European equity futures are struggling on Monday, consolidating after major indices clocked their biggest weekly gain in two months last week.

Euro STOXX 50 futures are down 0.6%. Futures on Germany's DAX are also losing 0.6% after the index closed at a

record high

on Friday.

With a U.S. market holiday and a lack of major data releases in Europe, focus is falling on geopolitics as U.S. Secretary of State Antony Blinken wraps up his

trip to China

, where a meeting with Chinese President Xi Jinping might be in the offing.

In company news, AstraZeneca will be in focus after the Financial Times reported the drugmaker is drafting a plan to

spin off its China business.

Attention will also be on aerospace and defence names, as the week-long Paris Airshow kicks off.

(Samuel Indyk)

READY FOR MORE RATE HIKES, AND ONE CUT (0554 GMT)

It's been predictably subdued in Asia as a U.S. holiday provides a convenient excuse for stocks to consolidate recent hefty gains before a bevy of central bank meetings this week. Most indices are down, with the Nikkei off modestly having climbed 22% over a 10-week streak to hit 33-year highs.

S&P 500 futures were also flat having risen for five weeks in a row, while the NASDAQ has notched eight weeks of gains. Those rallies are narrowly based, though, with just nine large-cap stocks making up 30% of the S&P 500. It's hard to call the index a "diversified" investment any more.

Markets are watching U.S. Secretary of State Antony Blinken's visit to Beijing, though you know expectations are low when it's newsworthy that a Chinese diplomat deigned to shake his hand.

Among currencies, the yen downtrend remains alive and well as the euro and dollar both make new highs, albeit by just a few ticks. Further losses look likely unless and until the Bank of Japan takes another step toward tightening, which many Western analysts see as possible in July. Governor Kazuo Ueda, however, seemed to set a high bar for a move last week by saying his outlook for inflation would have to shift "sharply" to justify a move.

The coming week is also jammed with central bank action, led by China on Tuesday where prime loan rates are expected to be cut by 10 basis points. That might be pushing on string given mortgage rates have already fallen markedly and lower rates only eat into the return on household savings. Markets are really hanging on for more fiscal stimulus to revive growth, as it has so often in the past.

Federal Reserve Chair Jerome Powell appears before lawmakers on Wednesday and Thursday and may again try to convince markets that two more quarter-point rate hikes are really, honestly, cross-my-heart likely.

Futures seem unimpressed with just 21 basis points of tightening priced in by September, though one final hike in July is rated as a decent 70% chance.

In contrast, markets are baying for the Bank of England to hike when it meets on Thursday, the only question being by 25 or 50 basis points. Futures lean toward the smaller move to 4.75% but also have rates rising to at least 5.75% given stubborn inflation and surging wages.

Gilt yields have already hit 15-year highs, causing havoc in the UK mortgage market and lifting the government's already astronomical borrowing costs.

Rate hikes are also expected in Norway and Switzerland this week, perhaps by 50 basis points, though that will likely pale in comparison to Turkey's central bank as some analysts see rates rising from the current 8% to as much as 25%.

Key developments that could influence markets on Monday:

- ECB board member Isabel Schnabel, ECB Vice President Luis de Guindos and ECB chief economist Philip Lane are all speaking

- U.S. stock and bond markets are closed, while the NAHB housing market index for June is due

(Wayne Cole)

More News
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.